ALX Oncology Holdings Inc.
News
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
Globe Newswire SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ( ALX Oncology or the Company ) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...\n more…
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Globe Newswire Clinical study is evaluating ALX Oncology's investigational CD47-blocking therapeutic with Sanofi's approved CD38 monoclonal antibody in patients with multiple myelomaSOUTH SAN FRANCISCO, Calif...\n more…
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Brokerages
Ticker Report ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat...\n more…
California State Teachers Retirement System Has $254,000 Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO)
Ticker Report California State Teachers Retirement System increased its holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 413.8% in the first quarter, according to its most recent Form 13F...\n more…
HC Wainwright Analysts Reduce Earnings Estimates for ALX Oncology Holdings Inc. (NASDAQ:ALXO)
Ticker Report ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Stock analysts at HC Wainwright dropped their Q3 2024 earnings per share (EPS) estimates for shares of ALX Oncology in a research note issued...\n more…